Recepton sp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2016-02-08
Share capital
10,000.00 PLN
Average employment (people)
3 (2025)
Activity description

Recepton offers biologically active proteins in stable cell lines, along with services for immune checkpoint receptors, custom-made proteins, protein analytics, organic synthesis, cell line development, and rational drug design. The company also describes case studies involving GITR/GITRL and CD82 protein production.

Registered address
ul. Trzy Lipy 3, 80-172 Gdańsk, Poland
Email
Phone
Electronic delivery address
AE:PL-49043-55084-VSGGH-19

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)$0
Profit allocationCovers prior losses

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 17 days late).

  • 202502/07/2026
  • 202410/07/2025
  • 202329/06/2024
  • 202229/06/2023
  • 202101/08/2022
  • 202022/06/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Division · Scientific research and development1,060 / 1,943
Top 55%
City · Gdańsk5,365 / 7,502
Top 72%
Voivodeship · Pomorskie14,993 / 20,062
Top 75%
Country · Poland219,836 / 297,069
Top 74%

Results vs industry

Revenue
This companyUSD 50.61kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD 973.28MedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 49.64kMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 107.11kMedianUSD 134.71kAverageUSD 3.04m

Offer

  • Immune checkpoint receptors
  • Immune proteins
  • Small-molecule inhibitors
  • Fusion proteins
  • Cancer immunotherapy research

Websites

Job offers

The company lists 4 job openings on its own careers page: receptonbiotech.com/carrers.

Position
Scientist – Drug discovery
Scientist – In silico drug design
Scientist – Organic chemistry

Authorized Representatives

Tadeusz Holak age 80 – President of the Management Board

Manner of representation

In the case of a one-person management board, declarations of will on behalf of the company are made by the member of the management board. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make a declaration of will on behalf of the company.

Ownership

OwnerSharesShare valueStake
Fundacja Rodzinna Agnieszki i Adama Krzanowskich
48$648.3024%
47$634.7923.5%
42$567.2621%
47$634.7923.5%
Katarzyna Bitner-Przybylska
10$135.065%
Przemysław Bielski
6$81.043%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2018-03-16.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

6 public aid cases recorded, with a total value of $2,995,076.

PurposeGross amount
Aid for research and development projects: industrial research
$346.5K
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$12,974
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$628

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Explorna Therapeutics sp. z o.o.
Acteryon sp. z o.o.
Nanoexpo sp. z o.o.
Personather sp. z o.o.
Fly-Gen sp. z o.o.
Onconick sp. z o.o.
Biolabic sp. z o.o.
Unistart sp. z o.o.
Meditransfer Centrum Transferu Technologii Iitd sp. z o.o.
Nanovelos S.A.

Change history

DateEvent
2019-11-14Address change
2018-03-05Address change
2018-03-05Share capital increase
2018-03-05PKD change
2016-02-08Entered in the register

FAQ

Last updated: 2026-07-04